2025 Q4 -tulosraportti
UUTTA
6 päivää sitten
‧1 t 1 min
7,95 DKK/osake
Irtoamispäivä 27.3.
3,70%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
3 009 039
Myynti
Määrä
2 927 154
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 000 | NRD | NRD | ||
| 86 | - | - | ||
| 514 | - | - | ||
| 50 | - | - | ||
| 50 | - | - |
Ylin
312VWAP
Alin
302,85VaihtoMäärä
2 122,9 6 921 069
VWAP
Ylin
312Alin
302,85VaihtoMäärä
2 122,9 6 921 069
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenWhat do you gentlemen think about the CFO having sold for 8mill - surely not exactly a sign that he believes in it / progress for Novo ? (Well aware that the man is subject to special rules regarding buying/selling)
- ·2 t sittenIn the annual report, the Wegovy pill was at 170.000, and now 1 week later with the new prescription figures +the unknown ones, they have gained 76.000 new ones💪🏻 “Doustdar said around 246,000 patients are currently on the company’s Wegovy pill, which launched at the beginning of January and is already outpacing the early rollouts of existing GLP-1 injections.”·56 min sittenThere are no figures out before Friday.
- ·2 t sittenAgree that it's a good interview on Fox, and really good that he steps up and makes sure to get into the media in the USA. I don't quite understand the background for Novo continuing to highlight patient safety as a problem with compound products. Of the 1.,5 million people who take compounds, how many have received an impure product that has led to complications? If there was a problem, wouldn't we have heard about it from sick compourd users?
- 2 t sitten2 t sittenThe gap is closing $NVO $LLY The latest weekly prescription data (New-to-Brand or NBRx) for the week ending Jan 30 is out, and it confirms the thesis we have seen since the start of the year: momentum has shifted. For the last six months, the bear case on Novo Nordisk was simple: "Lilly is winning 70% of the new patients." That argument no longer holds. The "starter dose" dead heat: - The most important leading indicator for future market share is "starter doses" (new patients entering therapy). • Zepbound starters: 42’164 (+0.5% WoW) • Wegovy starters: 41’867 (+2% WoW) The gap is now less than 300 prescriptions. We are effectively at parity. Zepbound’s share of the starter market has gone down to 50.2%, meaning the market is now a true 50/50 duopoly again, rather than a Lilly monopoly. The Oral catalyst: The driver of this resurgence is clear. 21’153 of those new Wegovy starters were for the Oral pill. Nearly half of all new patients entering the Wegovy ecosystem are bypassing the needle entirely. This validates the "frictionless" thesis: at $149, the pill is unlocking a demographic that Zepbound even with vials simply is not reaching. No cannibalization: Importantly, the data shows that the pill is additive. The high proportion of oral starters combined with the stability of the overall franchise suggests that existing pen users are staying put, while the pill is adding up the new to therapy patients. Novo did not just stop the bleeding, they have successfully deployed a new tool that has neutralized Lilly’s momentum in less than 30 days. Strong funnel momentum for Novo.
- ·3 t sittenOur beloved CFO has sold shares for over 8 million. I will probably never be completely fond of that man. He is also a disaster when there are earnings presentations. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Karsten Munk Knudsen 2 Reason for the notification a) Position/status Executive Vice President, Chief Financial Officer (CFO) b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A/S b) LEI 549300DAQ1CVT6CXN342 4 Details of the transaction(s) a) Description of the financial instrument, type of instrument, Shares Identification code Novo Nordisk B DK0062498333 b) Nature of the transaction Sale of shares c) Price(s) and volume(s) Price(s) Volume(s) DKK 315.60 26,246 d) Aggregated information Aggregated volume Price
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
6 päivää sitten
‧1 t 1 min
7,95 DKK/osake
Irtoamispäivä 27.3.
3,70%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenWhat do you gentlemen think about the CFO having sold for 8mill - surely not exactly a sign that he believes in it / progress for Novo ? (Well aware that the man is subject to special rules regarding buying/selling)
- ·2 t sittenIn the annual report, the Wegovy pill was at 170.000, and now 1 week later with the new prescription figures +the unknown ones, they have gained 76.000 new ones💪🏻 “Doustdar said around 246,000 patients are currently on the company’s Wegovy pill, which launched at the beginning of January and is already outpacing the early rollouts of existing GLP-1 injections.”·56 min sittenThere are no figures out before Friday.
- ·2 t sittenAgree that it's a good interview on Fox, and really good that he steps up and makes sure to get into the media in the USA. I don't quite understand the background for Novo continuing to highlight patient safety as a problem with compound products. Of the 1.,5 million people who take compounds, how many have received an impure product that has led to complications? If there was a problem, wouldn't we have heard about it from sick compourd users?
- 2 t sitten2 t sittenThe gap is closing $NVO $LLY The latest weekly prescription data (New-to-Brand or NBRx) for the week ending Jan 30 is out, and it confirms the thesis we have seen since the start of the year: momentum has shifted. For the last six months, the bear case on Novo Nordisk was simple: "Lilly is winning 70% of the new patients." That argument no longer holds. The "starter dose" dead heat: - The most important leading indicator for future market share is "starter doses" (new patients entering therapy). • Zepbound starters: 42’164 (+0.5% WoW) • Wegovy starters: 41’867 (+2% WoW) The gap is now less than 300 prescriptions. We are effectively at parity. Zepbound’s share of the starter market has gone down to 50.2%, meaning the market is now a true 50/50 duopoly again, rather than a Lilly monopoly. The Oral catalyst: The driver of this resurgence is clear. 21’153 of those new Wegovy starters were for the Oral pill. Nearly half of all new patients entering the Wegovy ecosystem are bypassing the needle entirely. This validates the "frictionless" thesis: at $149, the pill is unlocking a demographic that Zepbound even with vials simply is not reaching. No cannibalization: Importantly, the data shows that the pill is additive. The high proportion of oral starters combined with the stability of the overall franchise suggests that existing pen users are staying put, while the pill is adding up the new to therapy patients. Novo did not just stop the bleeding, they have successfully deployed a new tool that has neutralized Lilly’s momentum in less than 30 days. Strong funnel momentum for Novo.
- ·3 t sittenOur beloved CFO has sold shares for over 8 million. I will probably never be completely fond of that man. He is also a disaster when there are earnings presentations. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Karsten Munk Knudsen 2 Reason for the notification a) Position/status Executive Vice President, Chief Financial Officer (CFO) b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A/S b) LEI 549300DAQ1CVT6CXN342 4 Details of the transaction(s) a) Description of the financial instrument, type of instrument, Shares Identification code Novo Nordisk B DK0062498333 b) Nature of the transaction Sale of shares c) Price(s) and volume(s) Price(s) Volume(s) DKK 315.60 26,246 d) Aggregated information Aggregated volume Price
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
3 009 039
Myynti
Määrä
2 927 154
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 000 | NRD | NRD | ||
| 86 | - | - | ||
| 514 | - | - | ||
| 50 | - | - | ||
| 50 | - | - |
Ylin
312VWAP
Alin
302,85VaihtoMäärä
2 122,9 6 921 069
VWAP
Ylin
312Alin
302,85VaihtoMäärä
2 122,9 6 921 069
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2025 Q4 -tulosraportti
UUTTA
6 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
7,95 DKK/osake
Irtoamispäivä 27.3.
3,70%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenWhat do you gentlemen think about the CFO having sold for 8mill - surely not exactly a sign that he believes in it / progress for Novo ? (Well aware that the man is subject to special rules regarding buying/selling)
- ·2 t sittenIn the annual report, the Wegovy pill was at 170.000, and now 1 week later with the new prescription figures +the unknown ones, they have gained 76.000 new ones💪🏻 “Doustdar said around 246,000 patients are currently on the company’s Wegovy pill, which launched at the beginning of January and is already outpacing the early rollouts of existing GLP-1 injections.”·56 min sittenThere are no figures out before Friday.
- ·2 t sittenAgree that it's a good interview on Fox, and really good that he steps up and makes sure to get into the media in the USA. I don't quite understand the background for Novo continuing to highlight patient safety as a problem with compound products. Of the 1.,5 million people who take compounds, how many have received an impure product that has led to complications? If there was a problem, wouldn't we have heard about it from sick compourd users?
- 2 t sitten2 t sittenThe gap is closing $NVO $LLY The latest weekly prescription data (New-to-Brand or NBRx) for the week ending Jan 30 is out, and it confirms the thesis we have seen since the start of the year: momentum has shifted. For the last six months, the bear case on Novo Nordisk was simple: "Lilly is winning 70% of the new patients." That argument no longer holds. The "starter dose" dead heat: - The most important leading indicator for future market share is "starter doses" (new patients entering therapy). • Zepbound starters: 42’164 (+0.5% WoW) • Wegovy starters: 41’867 (+2% WoW) The gap is now less than 300 prescriptions. We are effectively at parity. Zepbound’s share of the starter market has gone down to 50.2%, meaning the market is now a true 50/50 duopoly again, rather than a Lilly monopoly. The Oral catalyst: The driver of this resurgence is clear. 21’153 of those new Wegovy starters were for the Oral pill. Nearly half of all new patients entering the Wegovy ecosystem are bypassing the needle entirely. This validates the "frictionless" thesis: at $149, the pill is unlocking a demographic that Zepbound even with vials simply is not reaching. No cannibalization: Importantly, the data shows that the pill is additive. The high proportion of oral starters combined with the stability of the overall franchise suggests that existing pen users are staying put, while the pill is adding up the new to therapy patients. Novo did not just stop the bleeding, they have successfully deployed a new tool that has neutralized Lilly’s momentum in less than 30 days. Strong funnel momentum for Novo.
- ·3 t sittenOur beloved CFO has sold shares for over 8 million. I will probably never be completely fond of that man. He is also a disaster when there are earnings presentations. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Karsten Munk Knudsen 2 Reason for the notification a) Position/status Executive Vice President, Chief Financial Officer (CFO) b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A/S b) LEI 549300DAQ1CVT6CXN342 4 Details of the transaction(s) a) Description of the financial instrument, type of instrument, Shares Identification code Novo Nordisk B DK0062498333 b) Nature of the transaction Sale of shares c) Price(s) and volume(s) Price(s) Volume(s) DKK 315.60 26,246 d) Aggregated information Aggregated volume Price
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
3 009 039
Myynti
Määrä
2 927 154
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 000 | NRD | NRD | ||
| 86 | - | - | ||
| 514 | - | - | ||
| 50 | - | - | ||
| 50 | - | - |
Ylin
312VWAP
Alin
302,85VaihtoMäärä
2 122,9 6 921 069
VWAP
Ylin
312Alin
302,85VaihtoMäärä
2 122,9 6 921 069
Välittäjätilasto
Dataa ei löytynyt





